NCT04144348 - Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine, in Healthy Adults, and Children 12 to 59 Months of Age With Serologic Evidence of Prior Exposure | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 4, 2019

Primary Completion Date

December 20, 2022

Study Completion Date

December 20, 2022

Conditions

Human Metapneumovirus and Human Parainfluenza Infection

Interventions

BIOLOGICAL

mRNA-1653

Sterile liquid for injection

BIOLOGICAL

Placebo

Sterile liquid for injection

Trial Locations (19)

13057

Child Healthcare Assoc., Syracuse

13090

Child Healthcare Associates, Liverpool

13901

UHS Primary Care, Binghamton

20016

Meridian Clinical Research, Washington D.C.

27710

Duke Vaccine and Trials Unit, Durham

35205

Central Research Associates Inc, Birmingham

45414

Ohio Pediatric Research Assn Inc, Dayton

57117

Sanford Children's Hospital, Sioux Falls

67042

Heartland Research Associates LLC, El Dorado

67114

Heartland Research Associates LLC, Newton

68134

Meridian Clinical Research, LLC, Omaha

68510

Meridian Clinical Research, LLC, Lincoln

68701

Meridian Clinical Research, Norfolk

70006

MedPharmics, Metairie

77555

University of Texas Medical Branch (UTMB), Galveston

78240

Tekton Research Inc, San Antonio

78413

Crossroads Clinical Research, Corpus Christi

83404

Clinical Research Prime, Idaho Falls

84041

Tanner Clinic, Layton

All Listed Sponsors

lead

ModernaTX, Inc.

INDUSTRY